Locations:
Search IconSearch

Case Study: Skin Papules, Hand Neuropathy and Monoclonal Gammopathy

Scleromyxedema may cause extracutaneous symptoms

waxy papules on his hands, with associated skin thickening and finger flexion contractures on hand

By Soumya Chatterjee, MD, and Anthony P. Fernandez, MD, PhD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A 53-year-old man presented to the rheumatology clinic with a three-year history of an itchy rash, Raynaud’s phenomenon, dysphagia and a burning sensation in his hands.

Physical examination was notable for firm, greasy papules across his forehead that led to the formation of glabellar grooves (A).

Greasy papules on the patient's forehead  led to the formation of glabellar grooves
A. Papules across the forehead led to the formation of glabellar grooves.

There were waxy papules on his hands with associated skin thickening and finger flexion contractures (B., above). Similar skin changes were seen on his nose, lips, ears, trunk and feet. There was no telangiectasia or calcinosis.

Sensory neuropathy was present in his hands, arms and face. Tests of thyroid function were normal. Serum protein electrophoresis with immunofixation identified an IgG-λ monoclonal gammopathy, and a bone marrow biopsy was normal.

A subsequent skin-biopsy sample obtained from the right side of the neck showed dermal spindle-cell proliferation, thickened collagen fibers, fibrosis and perivascular inflammation (C, hematoxylin and eosin stain), as well as increased dermal mucin deposition (D, colloidal iron stain). A diagnosis of scleromyxedema was made.

Skin biopsy from the neck
C: A skin biopsy sample from the neck showed dermal spindle-cell proliferation, thickened collagen fibers, fibrosis and perivascular inflammation.
increased dermal mucin deposition
D. Increased dermal mucin deposition.

Scleromyxedema is a primary cutaneous mucinosis typically associated with a paraproteinemia. This type of sclerosing skin disorder may cause extracutaneous symptoms, as was seen in this patient.

Although infusions of intravenous immune globulin provided minimal relief initially, treatment with lenalidomide resulted in abatement of symptoms and reduction in paraproteinemia after four months.

This article was originally published in The New England Journal of Medicine, Nov. 23, 2023.

Advertisement

Related Articles

View of lower lip showing EMPD

Case Study: A Rare Case of Extramammary Paget Disease of the Oral Mucosa

Treatment insights from the ninth recorded EMPD case in 50 years

Medical illustration of hand with discolored fingers

Coexistence of Erythromelalgia and Raynaud’s Phenomenon

Treatment strategies require understanding of pathomechanisms

red blood cells floating around a DNA double helix

CHIP Cardiology Clinics Are Needed as CHIP Diagnoses Rise

Cleveland Clinic’s new dedicated program offers nuanced care for a newly recognized cardiovascular risk factor

LDL cholesterol particle with a DNA double helix on top of it

CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia Shows Safety and Preliminary Efficacy

First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3

Dr. Gerds with a patient
April 7, 2025/Cancer/Blood Cancers

Positive Results from Phase 3 Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Myelofibrosis cells
March 18, 2025/Cancer/Blood Cancers

Personalizing Treatment of Myelofibrosis-Associated Anemia

Combination therapy may help address underlying disease

Basal cell carcinoma
March 14, 2025/Cancer/Radiation Oncology

Definitive Radiation Therapy Effective for Treating Locally Advanced Basal Cell Carcinoma

Major study demonstrates importance of having a multidisciplinary approach to treatment for large, locally advanced tumors

Dr. Gerds - hematologist at Cleveland Clinic
December 2, 2024/Cancer/Blood Cancers

Looking Forward: Advances and Obstacles in Blood Cancer Treatment

What’s coming up at ASH and beyond

Ad